Alpha Cognition (ACOG) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Alpha Cognition (ACOG) has outperformed Nkarta (NKTX) over the past year, gaining 19.4% versus a loss of 4.7%. Alpha Cognition is the larger company by market cap ($196.9 million vs $161.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | NKTX |
|---|---|---|
| Share price | $9.04 | $2.25 |
| Market cap | $196.87M | $161.16M |
| 1-day change | 0.00% | +1.35% |
| YTD return | +39.08% | +21.62% |
| 1-year return | +19.42% | -4.66% |
| 5-year return | — | -87.73% |
| EPS (TTM) | $-1.32 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $3.72 |
| 52-week low | $4.50 | $1.70 |
| Distance from 52-week high | -10.85% | -39.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.12% | +381.33% |
| Average volume | 125.72K | 602.17K |
| Shares outstanding | 21.78M | 71.62M |
| Employees | 71 | 106 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACOG has outperformed NKTX by 24.1 percentage points over the past year.
- The two companies sit in different sectors: Alpha Cognition in Healthcare and Nkarta in Health Care.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
ACOG vs NKTX FAQ
Which is bigger, Alpha Cognition or Nkarta?
Alpha Cognition (ACOG) is larger, with a market capitalization of $196.87M compared with $161.16M for Nkarta (NKTX).
Which stock has performed better over the past year, ACOG or NKTX?
ACOG returned +19.42% over the past 12 months, compared with -4.66% for NKTX (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and Nkarta in the same industry?
No. Alpha Cognition is in the Healthcare sector, while Nkarta is in Health Care.